Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wider Than AZ’s PACIFIC – Novartis Has Broad NSCLC Plans For Canakinumab

Executive Summary

Novartis is taking its unexpected CANTOS cancer findings for canakinumab and running with them to Phase III in an adjuvant lung cancer setting that is broader that AstraZeneca's PACIFIC study.

You may also be interested in...



Novartis Hopes For Canakinumab In Lung Cancer Nosedive

After deciding to examine canakinumab's potential in lung cancer on the back of the CANTOS cardiovascular trial, Novartis designed a major late-stage program in oncology for the interleukin-1 beta inhibitor. The second of those CANOPY trials has just come crashing down.

Novartis Hit By Canakinumab NSCLC Miss

The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.

Interview: Novartis Counts On AS and PsA For Cosentyx Growth

Novartis immunology chief Eric Hughes tells Scrip a wealth of data is showing that early treatment with Cosentyx can prevent the structural changes that lead to lack of mobility in ankylosing spondylitis and psoriatic arthritis patients.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel